Why PCOS Sits at the Centre of OHSS Teaching
Trainees are usually introduced to OHSS through its mechanism, because the mechanism explains both the risk profile and every prevention strategy that follows. The syndrome is understood in the peer-reviewed literature indexed on PubMed as a cascade in which luteinised granulosa cells, under sustained hCG stimulation, release vasoactive mediators — vascular endothelial growth factor (VEGF) chief among them — that increase capillary permeability. Fluid moves out of the intravascular compartment; haemoconcentration, ascites and electrolyte disturbance follow in proportion to the scale of the response.
The teaching point that connects this mechanism to PCOS is straightforward: the size of the recruitable follicle cohort largely determines the size of the potential cascade. Patients with PCOS or PCOM typically carry a high antral follicle count and elevated anti-Müllerian hormone (AMH), reflecting a large pool of gonadotrophin-responsive follicles, and their ovaries are often notably sensitive to exogenous stimulation. Trainees therefore learn to think of OHSS risk not as a property of a drug or a protocol in isolation, but as an interaction between a responsive ovary, the stimulation applied to it and — critically — the nature and timing of the trigger and any subsequent hCG exposure. Framed this way, PCOS is not an exotic edge case in stimulation teaching; it is the scenario against which the whole prevention toolkit is taught.
Recognising the High-Responder Phenotype: What Trainees Are Taught to Assess
Before any protocol decision, trainees are taught to build a structured picture of predicted ovarian response from the baseline work-up. The elements are familiar, but the educational emphasis is on synthesis rather than any single number.
The habit instructors work particularly hard to instil is documentation: a predicted high responder should be identified as such in the treatment plan before stimulation begins, with the prevention strategy chosen prospectively rather than improvised at trigger. The elements of that structured picture are these.
- Anti-Müllerian hormone (AMH) — guidance from ESHRE on ovarian stimulation for IVF/ICSI discusses AMH as a marker of predicted high response. Trainees learn to interpret it in context: assay variability, recent hormonal treatment and the difference between a laboratory value and a clinical phenotype are all standard teaching caveats.
- Antral follicle count (AFC) — a baseline ultrasound assessment of the antral follicle pool is taught alongside AMH as the second pillar of response prediction, with attention to scanning technique and inter-observer variability.
- PCOS diagnosis and PCOM — trainees are taught to distinguish the full syndrome, diagnosed against recognised criteria, from isolated polycystic morphology on ultrasound, and to note that, for the narrow purpose of response prediction, morphology alone still signals a large recruitable cohort.
- History of previous response — where the patient has had a prior stimulated cycle, the observed response (follicle numbers, oocyte yield, any previous OHSS or cycle modification) is treated as informative evidence about future behaviour under stimulation.
- Contextual factors — age, body weight and endocrine features are taught as modifiers that shape dosing decisions rather than as independent risk markers of equal weight.
Stratifying Risk: The Early/Late Framework
Alongside phenotype recognition, trainees learn a conceptual framework that organises OHSS by timing, because timing points to cause and cause points to prevention. Early OHSS is understood as a consequence of the ovarian response to stimulation combined with the trigger — classically an hCG trigger acting on a large follicle cohort. Late OHSS is understood as being driven by endogenous hCG from an implanting pregnancy, which is why it can develop or worsen after an apparently uneventful retrieval.
This framework, presented in ESHRE and ASRM educational material and in the wider literature on PubMed Central, does real work in training. It explains why substituting the trigger primarily addresses early OHSS; why deferring embryo transfer addresses the late form; and why the two strategies are so often taught together for the highest-risk patients. Trainees who can articulate the early/late distinction can usually also explain, unprompted, why no single intervention removes risk entirely — a point examiners and supervisors tend to probe.
GnRH-Antagonist Protocols as the Default Framework
For predicted high responders, trainees learn that guidance from ESHRE favours GnRH-antagonist co-treatment as the starting framework, for a reason that is more strategic than pharmacological: an antagonist cycle keeps the pituitary responsive, which preserves the option of triggering final oocyte maturation with a GnRH agonist instead of hCG. A long-agonist protocol closes that door in advance. In teaching sessions this is often presented as a decision made at day one that determines what rescue options exist at day ten — a useful habit of forward planning that generalises well beyond OHSS. A structured comparison of the main stimulation frameworks, and where each sits in contemporary practice, is set out in our companion overview of ovarian stimulation protocols for clinicians.
The GnRH-Agonist Trigger
The agonist trigger is taught as a substitution of central importance in high-responder management. Mechanistically, a bolus of GnRH agonist displaces the antagonist and provokes an endogenous surge of luteinising hormone (and follicle-stimulating hormone) that matures the oocytes, but the surge is short-lived compared with the sustained luteotrophic activity of injected hCG. The corpora lutea therefore receive far less of the stimulus that drives the VEGF cascade, and the literature summarised in ESHRE and ASRM documents describes a marked reduction in early OHSS when the agonist trigger is used in antagonist cycles.
Trainees are taught two accompanying caveats with equal emphasis. First, the same short surge produces luteolysis, so the luteal phase after an agonist trigger is deficient by design; the management of that deficiency — modified luteal support or, more commonly in the highest-risk group, avoidance of fresh transfer altogether — must be planned at the moment the trigger is chosen, not afterwards. Second, any strategy that reintroduces hCG after an agonist trigger reintroduces a measure of the risk the substitution was meant to remove, which is why such approaches are taught cautiously and case by case.
Freeze-All and Cycle Segmentation
The freeze-all strategy — cryopreserving all suitable embryos and deferring transfer to a subsequent cycle — is taught as the intervention aimed squarely at late OHSS. If no fresh transfer takes place, there is no implanting pregnancy in the stimulated cycle and therefore no endogenous hCG to drive the late form of the syndrome. Trainees learn that this approach became practical at scale because vitrification made embryo cryopreservation reliable enough to build a strategy on, and embryologists in training study the associated laboratory workflow — witnessing, labelling, storage governance and the handling requirements of closed vitrification systems — as part of the same teaching block. The combination of agonist trigger plus freeze-all is presented in contemporary guidance as the coherent pairing for the highest-risk patients, with the explicit caveat that “lower risk” is the honest description, not “no risk”.
Dose Individualisation and Adjunctive Measures
Finally, trainees learn that prevention begins with the starting dose. Gonadotrophin dosing individualised to AMH, AFC and body weight is discussed in ESHRE guidance as a means of moderating the response of a predicted high responder from the outset, and supervisors typically teach a bias towards cautious starting doses with planned review, rather than aggressive doses with rescue in mind. Adjunctive measures — including the studied role of dopamine-agonist administration around trigger, and older techniques such as coasting — are presented from the literature as secondary tools whose place is defined case by case, never as substitutes for protocol choice, trigger choice and segmentation.
What Trainees Observe in Supervised Practice
Classroom frameworks become durable when trainees see them applied. In supervised stimulation clinics, trainees observe how monitoring findings — a rapidly enlarging follicle cohort, a steep oestradiol trajectory, an unexpectedly brisk early response — are translated into decisions: dose reduction, a switch of planned trigger, a move to segmentation, or occasionally cycle cancellation when the risk profile justifies it. They also observe the counselling conversation in which these changes are explained to the patient by the responsible clinician, which is itself a taught skill.
Trainees are additionally expected to recognise the clinical picture of established OHSS — abdominal distension and discomfort, nausea, reduced urine output, haemoconcentration on laboratory testing — well enough to escalate appropriately to the supervising team. The educational objective at this stage is pattern recognition and escalation, not independent management: responsibility for the patient remains with the accountable clinicians throughout.
Continuing Your Training in Ovarian Stimulation
The PCOS–OHSS relationship rewards structured study because it draws together almost everything a stimulation curriculum contains: response prediction, protocol selection, trigger pharmacology, luteal-phase physiology, cryopreservation strategy and the discipline of prospective planning. Clinicians who can reason through a predicted high responder — from baseline markers to a documented prevention plan — have usually acquired a framework that serves them across the whole of ovarian stimulation practice.
For physicians and embryologists who want to consolidate this material in a supervised clinical setting, the fine-ART Masterclass is a two-day, hands-on training programme delivered with Centrum Clinic in Ankara, in which participants work on real cases under supervision across the reproductive-medicine pathway, including stimulation planning and structured observation of the embryology laboratory.